Kisqali HR+/HER2- Early Breast Cancer Results (NATALEE) – Guidelines+ Trials Spotlight
On September 17, 2024, the US Food and Drug Administration (FDA) granted approval for Novartis’s Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of individuals with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early cancer (EBC) at high risk of recurrence, including those with node-negative […]